The adoption of chronic fatigue syndrome/myalgic encephalomyelitis case definitions to assess prevalence: a systematic review

Author
Johnston, Samantha, Brenu, Ekua, R. Staines, Donald, Marshall-Gradisnik, Sonya

Published
2013

Journal Title
Annals of Epidemiology

DOI
https://doi.org/10.1016/j.annepidem.2013.04.003

Copyright Statement
Copyright 2013 Elsevier. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.

Downloaded from
http://hdl.handle.net/10072/55530
The adoption of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis case definitions to assess prevalence: A systematic review

Johnston, S¹, Brenu EW¹, Staines DR¹,², Marshall-Gradisnik, S¹

¹ Griffith Health Institute, School of Medical Sciences, National Centre for Neuroimmunology and Emerging Diseases, Griffith University, Parklands, QLD, Australia
² Gold Coast Public Health Unit, Queensland Health, Robina, QLD, Australia

Correspondence: Samantha Johnston, National Centre for Neuroimmunology and Emerging Diseases, Centre for Medicine and Oral Health, Griffith University, Southport, QLD, Australia, 4215; Phone: +617 56780414; Fax: +617 55528908; Email: samantha.johnston3@griffithuni.edu.au

Word count: 3,064 (including references)
Abstract word count: 210 (including references)
Tables: 1
Figures: 1
Abstract

Purpose: Prevalence estimates have been based on several case definitions of Chronic Fatigue Syndrome (CFS). The purpose of this paper is to provide a rigorous overview of their application in prevalence research.

Methods: A systematic review of primary studies reporting the prevalence of CFS since 1990 was conducted. Studies were summarized according to study design, prevalence estimates, and case definition used to ascertain cases.

Results: Thirty one studies were retrieved and eight different case definitions were found. Early estimates of CFS prevalence were based on the 1988 CDC [1], Australian [2], and Oxford [3]. The 1994 Centers for Disease Control and Prevention (CDC) [4] however, has been adopted internationally, as a general standard. Only one study has reported prevalence according to the more recent, Canadian Consensus Criteria (CCC) [5]. Additional estimates were also found according to definitions by Ho-Yen [6], the 2005 CDC empirical definition [7], and an epidemiological case definition (ECD) [8].

Conclusion: Advances in clinical case definitions during the past 10 years such as the CCC [5] has received little attention in prevalence research. Future assessments of prevalence should consider adopting more recent developments, such as the newly available International Consensus Criteria (ICC) [9]. This could improve the surveillance of more specific cases found within CFS.

Key words: Chronic Fatigue Syndrome; Myalgic Encephalomyelitis; Systematic Review; Prevalence; Case definition

Selected abbreviations and acronyms: CFS, Chronic Fatigue Syndrome; ME, Myalgic Encephalomyelitis; CDC, Centers for Disease Control and Prevention; CCC, Canadian Consensus Criteria; ICC, International Consensus Criteria
Introduction

Chronic Fatigue Syndrome (CFS) represents a complex illness that has traditionally been described as debilitating fatigue, accompanied by a combination of symptoms. In the absence of a biological marker for the illness, case definitions have remained the predominant tool used to ascertain cases for clinical and epidemiological research. The first case definition for CFS was released in 1988 by the Centers for Disease Control and Prevention (CDC) [1]. It described all the clinical characteristics of what was known as chronic Epstein-Barr virus syndrome, but a link with the virus itself could not be established. Hence, the CDC proposed the term CFS for the illness, to remove the association with Epstein-Barr virus [1]. Accordingly, the 1988 CDC [1] described a new onset of debilitating fatigue of at least 6 months, accompanied by a minimum of eight, mostly flu like symptoms.

The Australian definition released in 1990 [2], included the same requirements for fatigue, accompanied by neuropsychiatric symptoms such as short term memory loss and difficulties concentrating. This was shortly followed by definitions from researchers in the United Kingdom, who maintained interest in a causal relationship with an infection. A definition by Ho-yen proposed in 1990 [6], is similar to the Australian [2], but required supporting evidence from case history, or clinical/laboratory evidence of a possible viral infection. The 1991 Oxford definition [3] on the other hand, only required the presence of debilitating fatigue for 6 or more months for CFS. It also featured additional criteria for a subset of CFS that it referred to as Post-Infectious Fatigue Syndrome. This required laboratory confirmation of an infectious agent.

In 1994, the CDC revised its 1988 definition [1]. It maintained criteria for fatigue, but reduced the required number of symptoms to four of the following: post-exertional malaise; unrefreshing sleep; impairment of short-term memory or concentration; muscle pain; joint pain; headaches; tender lymph nodes; and sore throat [4]. This has remained the current definition of the CDC, despite their development of an empirical definition in 2005 [7]. This definition introduced the use of three standard
measures to fulfill the same criteria of the 1994 definition [4], according to: symptoms using the CFS Symptom Inventory [10]; disability using the Short Form 36 survey [11]; and fatigue using the Multidimensional Fatigue Inventory [12]. The use of standard measures has also been proposed in an epidemiological case definition (ECD) published by UK researchers in 2007 [8] for severe fatigue, a reduction in pre-illness activity, myalgia, muscle weakness, joint pain, and swollen lymph nodes.

While many of these definitions were developed to select adult cases in a research setting, advances have been made in definitions for use in clinical diagnosis. In 2003, the Canadian Consensus Criteria (CCC) [5] was released. As studies were found to also refer to Chronic Fatigue Syndrome as Myalgic Encephalomyelitis, the definition adopted the hybrid term Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) to describe the illness. It also suggested that a reduced duration of illness of 3 months would be appropriate for diagnosing cases in children, compared to 6 months for adults. It included some of the symptoms described in the 1994 CDC such as fatigue, post-exertional malaise, sleep dysfunction, and pain; but introduced additional symptoms relating to neurocognitive, autonomic, neuroendocrine and immune manifestations [5]. In doing so, it described an illness that affects multiple systems of the body.

A revised version became available in 2011, and renamed the International Consensus Criteria (ICC) [9]. Moving away from the previous hybrid model of ME/CFS, it suggested that ME be recognized as a distinct illness by removing those that fulfill the ICC, from the broader category of CFS described in previous definitions [1-4, 7]. Accordingly, a number of significant changes were made. Duration of illness was no longer required, and the symptoms of chronic fatigue and post-exertional malaise commonly used to describe CFS, were replaced with a set of criteria for post-exertional neuroimmune exhaustion (PENE). Additional symptoms were reclassified under three categories of neurological impairment; immune or gastro-intestinal or genitourinary impairment; and energy metabolism or transport impairments. It is also the first definition to introduce several categories for severity, and more specific criteria for the diagnosis of cases in children.
Prevalence assessment specific for CFS commenced with the release of the 1988 CDC definition, and has since relied on the quality of definitions that are available. When interpreting prevalence estimates, it is therefore important to understand the substantial differences that are found between definitions in terms of the symptoms they emphasize, and inclusion criteria. The purpose of this systematic review is to provide a rigorous overview on reported CFS prevalence, according to the case definitions used. It is particularly interested in whether prevalence studies have incorporated new developments in clinical definitions into their design. This will help evaluate the reliability of available estimates and how the role of case definitions in future surveillance of the illness can be improved.

**Methods**

Medline, Embase and PubMed Central databases were systematically searched using the Medical Subject Headings (MeSH) terms of ‘Chronic Fatigue Syndrome’ (which also captures Myalgic Encephalomyelitis) and ‘prevalence’. Titles and abstracts were screened for potential studies whose primary outcome was to detect the prevalence of CFS in community or primary care samples. Full texts were then examined for suitability. Secondary search then commenced on reference lists of the studies selected for review. To capture the beginning of prevalence research and the progress of different countries, no restrictions were made to the date and language if detailed summaries in English were available. As this review focuses on CFS prevalence in the general population, it did not include assessment in groups of special interest. Data were summarized according to sample setting (community, primary care), sampling method (prospective vs. retrospective), age, estimated prevalence, and the case definition used to ascertain cases.
Results

Literature search

The search returned 218 records, including 40 prevalence studies that were assessed for eligibility. Of these 9 exclusions were made: one study was based on a case-control design that was considered bias for determining prevalence [13]; one study that did not disclose which definition they used [14]; and 7 studies based on special interest groups [15-21]. The remaining 31 studies contributed a total of forty-one prevalence estimates, and were published between 1990 and 2011 (Table 1). Of these, 19 were community based [22-40]; 12 were primary-care based [2, 41-51]. Twenty nine were prospective [2, 22-49, 51] and 2 retrospective [24, 50]. Twenty five studies assessed cases in adults [2, 23-25, 27, 28, 30, 32, 33, 35-45, 47-51]; and 7 studies assessed cases specifically in children and adolescents (<18 years) [22, 26, 29, 31, 34, 36, 46].

Case definitions identified

In total, eight different definitions have were identified in the studies (Table 1): the 1988 CDC [1], Australian [2], Ho-Yen [51], Oxford [3], the 1994 CDC [4], the 2005 CDC empirical [7], the CCC [5], and ECD [8]. This does not include approximate versions of the 1988 CDC [50], and 1994 CDC [24] definitions. In adult studies: eight estimates [35, 39, 40, 44, 45, 48, 49, 52] are based on the 1988 CDC [1]; three estimates [2, 35, 49] according to the Australian [2]; four estimates [35, 39, 47, 49] based on the Oxford [3], and only one estimate [51] based on the Ho-Yen [6]. Since 1997, 20 estimates [22, 23, 25, 26, 28-39, 41-43] are available using the 1994 CDC [4]. Only one prevalence estimate is available for each of the 2005 CDC empirical [7, 27], the CCC [5, 41] and the ECD [8, 41] definitions. After the publication of these studies, the ICC [9] became available.
Of these, four studies applied several definitions to report prevalence. Bates et al. [49] reported estimates of 0.3% (1988 CDC [1]), 0.4% (Oxford [3]) and 1.0% (Australian [2]). Kawakami et al. [39] estimated prevalence of 1.50% for both the Oxford [3] and Fukuda definitions [4], while no cases fulfilled the 1988 CDC [1]. Lindal et al. [35] reported estimates of 4.8% (Australian [2]), 2.4% (Oxford [3]), 1.4% (1994 CDC [4]) and 0% (1988 CDC [1]). Lastly, Nacul et al. [41] produced estimates of 0.19% (1994 CDC [4]), 0.11% (CCC [5]) and 0.03% (ECD [8]).

In studies based on children and adolescents, one [52] was based on the 1988 CDC [1]; the remaining six [22, 26, 29, 31, 34, 36] applied the 1994 CDC [4] and were published after the CCC [5] was released. One of the studies based on the 1994 CDC [4] reported 2 estimates of prevalence at baseline of 0.1% and at 6 months of 0.5% [26].

**Discussion**

**Case definitions in available prevalence**

This review found eight different case definitions have been used to report the prevalence of CFS. Inconsistent case definitions is predominant among the early studies and the variability this has caused in estimates is demonstrated by several studies [35, 39, 41, 49]. When compared to the 1994 CDC [4], Australian [2], and Oxford [3] definitions, the 1988 CDC [1] appears to have the lowest sensitivity, as it reports the lowest prevalence estimates [35, 39, 49]. The 1988 CDC [1] definition received particular criticism for its emphasis on fatigue, thereby not distinguishing CFS from other illnesses with unexplained fatigue [53]. Straus et al. [54] in particular, found that this led to the inadvertent selection of cases with high levels of psychiatric illness. The 1988 CDC [1] criteria for fatigue has also remained an issue, as it was adopted by subsequent definitions for CFS [2-6].

The Australian definition [2] was used to report the first formal prevalence estimate of CFS. Its symptom criteria is the most broad of the definitions, which has contributed to prevalence estimates at least two
times higher [35, 49] than the 1988 CDC [1], Oxford [3], and 1994 CDC [4] definitions. This, combined with an emphasis on neuropsychiatric symptoms has also meant the definition is bias in selecting cases with psychiatric disorders [55]. The Ho-yen [6] and Oxford [3] definitions aimed to address the low sensitivity of the 1988 CDC[1] criteria by requiring only two compulsory symptoms, as well as the overly inclusive criteria of the Australian [2] with additional laboratory confirmation of an infection. These definitions however, still lacked specificity, as many non-CFS cases with a post-viral illness could fulfill these criteria for CFS [56]. There also remains no consistent evidence that CFS shares a causal relationship with a virus [57].

As psychiatric disorders were identified as important source of confounding in CFS studies, the 1994 CDC [4] aimed to provide further clarification between the relationship of CFS and neuropsychiatric symptoms. It soon replaced previous definitions as studies adopted the 1994 CDC [4] as a general standard. This has enabled the comparison of prevalence estimates across geographies and sample settings. Its use in the past 10 years has remained consistent, despite the introduction of several new case definitions.

It is argued however, that the definition is still limited by its specificity, leading to the inconsistent selection of cases for research [58]. This is reflected in the observed variability found in reported prevalence estimates based on the 1994 CDC [4], that range between 0.19% [41] to 2.1% [42]. Some of these estimates however, are reported as the prevalence of “CFS-like” illness rather than true cases of CFS, to characterize cases that fulfill the criteria by self-reporting [25, 32, 38]. Further investigation on the specificity of the 1994 CDC definition [4] however, has found significant differences in simple clinical measurements between distinct clinical that all fulfilled the definition for CFS [59]. Further, it has been demonstrated that the definition was unable to distinguish between symptoms of post-exertional malaise, problems with sleep, memory and cognitive difficulties between cases of CFS and depression [60].
There are also concerns that a lack of explicit instructions has contributed to the inconsistent application of the definition [61]. This could be a reason for inflated estimates of CFS. A self-reporting survey in Hong Kong for example, reported prevalence as high as 6.4% in the community [30]. Moreover, a retrospective study was found to apply an approximate version of the 1994 CDC [4] to a national health survey, and reported a prevalence of 2.3% [24]. This version only included the presence of fatigue accompanied by concentration and/or short term memory difficulties, sleep issues, and pain. This only meets three of the eight possible symptoms specified in the 1994 CDC [4]. Therefore, caution must be taken when interpreting estimates of studies not only in the specificity of the definition used, but the methods used to apply them.

The 1994 CDC [4] has also received criticism for being revised by consensus rather than by new empirical findings [62]. The CCC [5] definition for ME/CFS however, was the first definition to devise its criteria from empirical evidence. Compared to the 1994 CDC [4], the CCC [5] has been shown to be more effective at selecting CFS cases with less psychiatric disorders, and more severe impairments in physical functioning, fatigue, neuropsychiatric, and neurological symptoms [63]. This is supported by the results of the only prevalence study to apply the CCC [5], where cases fulfilling the CCC [5] represented a distinct subgroup of 1994 CDC cases with more severe physical and cognitive symptoms [41].

Unlike the CCC definition [5] that has been shown to contribute more conservative prevalence estimates of CFS [41] than the 1994 CDC [4], the 2005 CDC empirical definition [7] has been attributed to significantly higher estimates of CFS [64]. Compared to one study reporting a prevalence of 0.4% in the United States (US) [37], a study that applied the 2005 CDC empirical [7] reported a US prevalence of 2.54% [27]. A suggested reason for this inflation is the 2005 CDC empirical [7] is more broad than the 1994 CDC [4], increasing its likelihood of including cases of psychiatric disorder [64]. This has been demonstrated in one study that found it misclassified 38% of diagnosed cases of Major Depressive Disorder as CFS [65]. Compared to the 2005 CDC empirical [7], the CCC [5] has also been
shown to more effectively discriminate between cases and non-cases of CFS; the 2005 CDC empirical [7] could only discriminate 79% of cases, while the CCC [5] was able to discriminate between 87% of cases [66].

Further, all prevalence studies of CFS in children and adolescents identified in this review [22, 29, 31, 34, 36, 52], have been based on definitions for adults [1, 4]. Its inability to adequately identify cases in children may be reflected in the results found by one study, who a reported higher prevalence of the illness after 6 months [26]. A lack of specific criteria may lead to the selection of cases whose conformity to the definition changes over time.

Although the CCC [5] definition was the first to adapt its criteria for use in children, it was still predominantly aimed at diagnosis in adults. Concerns about the inability to distinguish cases in children led to the development of the Pediatric Case Definition for ME/CFS [67]. Findings have suggested that it can distinguish between those with the illness and controls [68]. It has yet to be published in prevalence research.

The latest definition used in prevalence studies is the ECD [8], however the prevalence estimates were significantly lower than the 1994 CDC [4], and CCC [5] suggesting the case definition does not have the sensitivity required to provide valid estimates of CFS [41].

**Case definitions in future prevalence**

The findings of the review highlight several important issues in the development of prevalence studies. 1) Since definitions have changed over time, early estimates cannot be compared to recent ones. Accordingly, it is not possible to measure accurately how prevalence has changed over time. 2) The 1994 CDC [4] remains a standard definition for CFS, despite concerns about its limited specificity. This could be a potential source of bias in reporting prevalence. 3) Available reports of prevalence in children and adolescents may not be reliable, because they are based on criteria for adults.
Findings based on the CCC [5], indicate that it possesses the improved specificity needed in case definitions for research. A plausible reason for its late adoption in prevalence assessment is that it was primarily devised for clinical diagnosis. It relies on clinical verification of symptoms, as well as a laboratory protocol, which requires more resources to administer in a research setting. The current issues found in prevalence research however, may be improved through the adoption of such clinical definitions. It is proposed that the latest ICC definition for ME [9] be examined for its effectiveness in prevalence assessment. If systematically applied with the 1994 CDC, it could determine whether CFS has failed to capture more distinct cases of ME. The potential of the ICC [9] to select further subgroups for research in contrast to the 1994 CDC is displayed in Figure 1.

Figure 1: The 1994 CDC for CFS vs. the ICC definition for ME
The 1994 CDC [4] was devised in research for the selection of cases in adults. The ICC definition [5] was developed primarily for clinical diagnosis, but offers additional criteria for pediatric cases and severity for research.

Abbrev: CDC, Centers for Disease Control; ICC, International Consensus Criteria; CFS, Chronic Fatigue Syndrome; ME, Myalgic encephalomyelitis

The ICC [9] is the first definition to describe the illness in terms of severity, describing a substantial reduction in pre-illness activity levels as mild; a 50% reduction in pre-illness activity levels as moderate;
severe as mostly bedridden; and very severe as totally bedridden. How cases may differ in severity, has not been captured in prevalence research. Its classification of symptoms also enables research to examine how symptoms may vary in terms of pathophysiological dysfunction. The authors of the ICC [9] has also published a tool assist health professionals in its application known as the International Consensus Primer [57]. This could be of particular value in research, as an important issue has been inconsistent interpretation of previous definitions. Accordingly, the ICC [9] may be particularly affective in prevalence studies that are conducted in a primary care setting where clinicians are available to assess cases.

Conclusion

Available estimates of CFS prevalence are largely based on the 1994 CDC [4] definition that emphasize prolonged fatigue and a combination of broad non-specific symptoms. Recent developments in clinical definitions such as the CCC [5] and ICC [9] however, have moved away from this model of CFS and feature more specific symptoms that are multi-systemic in nature. This has received little attention in prevalence studies, despite findings that they may have improved effectiveness in selecting cases for research. This review proposes that a systematic approach be taken in future studies to adopt the ICC [9] definition in an effort to identify more specific cases of ME. The use of improved case definitions will contribute to more effective surveillance and provide further insight into the characteristics of the illness.
<table>
<thead>
<tr>
<th>Publ. year</th>
<th>First Author</th>
<th>Country</th>
<th>Age</th>
<th>Sample</th>
<th>Method</th>
<th>Reported prevalence (%)</th>
<th>Case definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Ho-yen [51]</td>
<td>UK</td>
<td>all</td>
<td>P</td>
<td>P</td>
<td>0.13</td>
<td>Ho-Yen [6]</td>
</tr>
<tr>
<td>1992</td>
<td>Price [50]</td>
<td>USA</td>
<td>18≤</td>
<td>P</td>
<td>R</td>
<td>0.0074</td>
<td>1988 CDC* [1]</td>
</tr>
<tr>
<td>1993</td>
<td>Bates [49]</td>
<td>USA</td>
<td>18≤</td>
<td>P</td>
<td>P</td>
<td>0.4</td>
<td>1988 CDC [1]</td>
</tr>
<tr>
<td>1993</td>
<td>Gunn [48]</td>
<td>USA</td>
<td>18≤</td>
<td>P</td>
<td>P</td>
<td>0.003</td>
<td>1988 CDC [1]</td>
</tr>
<tr>
<td>1995</td>
<td>Jason [40]</td>
<td>USA</td>
<td>18≤</td>
<td>C</td>
<td>P</td>
<td>0.20</td>
<td>1988 CDC [1]</td>
</tr>
<tr>
<td>1995</td>
<td>Lawrie [47]</td>
<td>UK</td>
<td>18≤</td>
<td>P</td>
<td>P</td>
<td>0.56</td>
<td>Oxford [3]</td>
</tr>
<tr>
<td>1997</td>
<td>Reyes [45]</td>
<td>USA</td>
<td>18≤</td>
<td>P</td>
<td>P</td>
<td>0.0052</td>
<td>1988 CDC [1]</td>
</tr>
<tr>
<td>1997</td>
<td>Versluis [44]</td>
<td>Netherlands</td>
<td>18≤</td>
<td>P</td>
<td>P</td>
<td>0.11</td>
<td>1988 CDC [1]</td>
</tr>
<tr>
<td>1998</td>
<td>Steele [38]</td>
<td>USA</td>
<td>18≤</td>
<td>C</td>
<td>P</td>
<td>0.23</td>
<td>1994 CDC [4]</td>
</tr>
<tr>
<td>1999</td>
<td>Jason [37]</td>
<td>USA</td>
<td>18≤</td>
<td>C</td>
<td>P</td>
<td>0.42</td>
<td>1994 CDC [4]</td>
</tr>
<tr>
<td>2003</td>
<td>Chalder [34]</td>
<td>UK</td>
<td>5-15</td>
<td>C</td>
<td>P</td>
<td>0.19</td>
<td>1994 CDC [4]</td>
</tr>
<tr>
<td>2006</td>
<td>Jordan [29]</td>
<td>US</td>
<td>5-17</td>
<td>C</td>
<td>P</td>
<td>0.06</td>
<td>1994 CDC [4]</td>
</tr>
<tr>
<td>2007</td>
<td>Reeves [27]</td>
<td>USA</td>
<td>18-59</td>
<td>C</td>
<td>P</td>
<td>2.54</td>
<td>2005 CDC [7]</td>
</tr>
<tr>
<td>2009</td>
<td>van't Leven</td>
<td>Netherlands</td>
<td>18≤</td>
<td>C</td>
<td>P</td>
<td>1.0</td>
<td>1994 CDC [4]</td>
</tr>
<tr>
<td>2011</td>
<td>Nacul [41]</td>
<td>UK</td>
<td>18-64</td>
<td>P</td>
<td>P</td>
<td>0.03</td>
<td>CCC [5]</td>
</tr>
</tbody>
</table>

a) P, primary care; C, community  
b) P, prospective; C, community  
c) CDC, Centers for Disease Control and Prevention; CCC, Canadian Consensus Criteria; ECD, Epidemiological Case Definition  
*author applied approximate version of definition
References